Overweight
Conditions
Interventions
Experimental group: 19 overweight girls, 11 normal weight girls, 13 overweight boys, 10 normal weight boys undergoing a combined training program consisting of strength training with 3 sets of 6-10 ma
Other
E02.760.169.063.500.387
Sponsors
Departamento de Educação Física (DEF), da Universidade Federal do Paraná (UFPR)
Faculdade de Educação Física da Universidade Estadual de Campinas
Eligibility
Age
13 Years to 17 Years
Inclusion criteria
Inclusion criteria: Conditions to participate in all evaluations and / or intervention; presentation of the informed consent form (TCLE) and free and informed consent form (TALE) signed; individuals of both sexes between, 13 and 17 years of age; pubertal staging Tanner IV; individuals classified as eutrophic (BMI <z-score +1) or overweight (BMI z-score +1); not presenting clinical conditions such as: established diagnosis of type 1 or type 2 diabetes, familial dyslipidemia and / or treatment with statins, Untreated or uncontrolled hypothyroidism / hyperthyroidism; obesity induced by other endocrine disorders, delayed significant puberty of any etiology requiring investigation and / or treatment, patients with a diagnosis or suspicion of growth hormone deficiency, severe asthma requiring frequent hospitalizations or use of systemic corticosteroids for more than 10 days, a history of current treatment or treatment with medications that may cause significant weight gain within three months prior to the screening visit, including corticosteroids (bariatric surgery less than 7-10 days), tricyclic antidepressants, antipsychotics and mood stabilizers, previous surgical treatment for obesity (Bariatric Surgery), known or suspected alcohol, drug or narcotic abuse, recent infections or the presence of acute inflammatory disease or chronic, genetic syndromes that lead to obesity.
Exclusion criteria
Exclusion criteria: To present some intercurrence that would make continuity of the intervention and / or evaluations impossible; participation in other activities that interfered in the results of the research such as (sports practice or systematic exercise, diets, other treatments); less than 70%.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected primary outcome 1 The outcome will be considered effective if observed between the group and time (any measured moment compared to the pre-intervention moment) with p-value less than 0.05 (variation of 5%), with a decrease in serum C-reactive protein in mg/dl, analyzed by the Enzyme-Linked Immunosorbent Assay (ELISA) technique.;Expected primary outcome 2 The outcome will be considered effective if observed between the group and time (any time measured compared to the pre-intervention time) with p value less than 0.05 (variation of 5%), with improvement of the serum metabolic profile (metabolits in mg/dl) evaluated by nuclear magnetic resonance. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected secundary outcome 1 Improvement in cardiorespiratory fitness assessed by the maximal oxygen consumption test (VO2) by gas analysis (ml / min / kg) from the observation of a variation of at least 5% in the pre- and post-intervention measurements;Expected secundary outcome 2 Maximum strength improvement (kilos) evaluated by the maximum repetition test from the observation of a variation of at least 5% in the pre- and post-intervention measurements;Expected secundary outcome 3 Improvement of body composition using plethysmograph and dual X-ray densitometry (DEXA) for analysis of fat-free mass and fat mass in kilograms (kg) and percentages (%) from the observation of a variation of at least 5% in the pre- and post-intervention measurements;Expected secundary outcome 4 Improvement of body composition using plethysmograph and dual X-ray densitometry (DEXA) for analysis of fat-free mass and fat mass in kilograms (kg) and percentages (%) from the observation of a variation of at least 5% in the pre- and post-intervention measurements;Expected secundary outcome 5 Improvement of clinical biochemical blood markers lipid profile (total cholesterol, triglycerides, HDL, LDL, VLDL (Mg / dl), glucose (mg / dl), blood count (g / dl and mm³), insulin (ui / ml) using kits and techniques commercially available from the observation of a variation of at least 5% in the pre- and post-intervention measurements;Expected secundary outcome 6 Insulin resistance decrease and insulin sensitivity increase using the index homeostasis model, QUICKI index, TYG index - glucose / triglycerides and Z score of metabolic syndrome (%) from the observation of a variation of at least 5% in the pre- and post-intervention measurements;Expected secundary outcome 7 Changes in serum peptides related to inflammation, such as tumor necrosis factor alpha (pg / ml), interleukin 6 (pg / ml) interleukin 10 (pg / ml), leptin / ml), adiponectin (ng / ml), Resistin (ng / ml) using high sensitivity ELI | — |
Countries
Brazil
Contacts
Public ContactWendell Lopes
Departamento de Educação Física da Universidade Estadual de Maringá
Outcome results
None listed